| c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. | breast, |
| Frequent amplification of C-erbB2 (HER-2/Neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections. | cervical, |
| Immunohistochemical expression of c-erbB-2 oncoprotein and EGF-R in pre- and postmenopausal breast cancer. | breast, |
| Expression of c-erbB-2 oncoprotein in human thyroid tumours. | thyroid, |
| Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. | None |
| Expression of c-erb B-2 oncoprotein in cancer of the larynx in relation to invasion of the cartilagenous framework and prognosis. | None |
| Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide. | None |
| HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. | None |
| The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. | None |
| Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. | None |
| The HER-2/neu story: from oncogene through prognostic marker to therapeutic strategy determinant and monoclonal therapy. | None |
| The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. | None |
| Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice. | None |
| Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. | None |
| Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. | None |
| Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. | None |
| Oncogenic activating mutations in the neu/erbB-2 oncogene are involved in the induction of mammary tumors. | None |
| [Relationship of C-erbB-2 oncogene overexpression to estrogen progesterone receptors in brease cancer and its prognostic significance]. | None |
| Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. | None |
| Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene. | None |